Research is investigating the mechanisms behind immune toxicity and systemic organ injury associated with checkpoint inhibitors, including PD-L1/CTLA-4. The studies appear to be exploring various aspects of immune checkpoint blockade, including its role in cancer therapy and potential risks such as myocarditis. The findings may have implications for the development of therapeutic approaches and the management of immune-related side effects in cancer treatment.